Revolution Medicines, Inc.
RVMD
$203.71
$1.710.85%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 14.81% | 16.62% | |||
| Gross Profit | -14.81% | -16.62% | |||
| SG&A Expenses | 8.85% | 51.84% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.46% | 23.12% | |||
| Operating Income | -13.46% | -23.12% | |||
| Income Before Tax | -41.99% | -24.37% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -41.99% | -24.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -41.99% | -24.37% | |||
| EBIT | -13.46% | -23.12% | |||
| EBITDA | -13.50% | -23.23% | |||
| EPS Basic | -33.37% | -23.47% | |||
| Normalized Basic EPS | -33.37% | -23.47% | |||
| EPS Diluted | -33.37% | -23.47% | |||
| Normalized Diluted EPS | -33.37% | -23.47% | |||
| Average Basic Shares Outstanding | 6.46% | 0.73% | |||
| Average Diluted Shares Outstanding | 6.46% | 0.73% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||